Quality of Life in MPN Comes of Age as a Therapeutic Target

Robyn M. Scherber, Holly L. Geyer, Ruben A. Mesa

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

BCR-ABL-negative myeloproliferative neoplasms include primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Clonal stem cell proliferation and dysregulated JAK/STAT molecular pathways characterize these hematologic malignancies. Symptoms experienced by patients are heterogeneous including excessive and disabling fatigue, early satiety, anorexia, pruritus, bone pain, night sweats, cachexia, abdominal pain and discomfort, and cognitive complaints. Patients also experience impaired quality of life along with decreased overall survival. New targeted drug therapies, including JAK2 inhibitors, have demonstrated remarkable success in alleviating the myeloproliferative neoplasm (MPN) symptomatic burden, reducing splenomegaly and improving quality of life while offering overall survival benefit. Within the USA, FDA approval has only been granted to use JAK2 inhibitors in intermediate- to high-risk myelofibrosis. However, given that low-prognostic-scoring patients have been shown to have considerable symptomology, there is a possibility that lower-risk patients may benefit from therapy. More than ever, the need for accurate MPN symptom burden assessment and subsequent addition of targeted therapies is critical in the treatment of MPNs. This article discusses the role of MPN symptom burden and quality of life as therapeutic targets in the context of recent MPN clinical advances.

Original languageEnglish (US)
Pages (from-to)324-330
Number of pages7
JournalCurrent Hematologic Malignancy Reports
Volume9
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Quality of Life
Polycythemia Vera
Primary Myelofibrosis
Neoplasms
Essential Thrombocythemia
Therapeutics
Cachexia
Symptom Assessment
Survival
Sweat
Splenomegaly
Anorexia
Hematologic Neoplasms
Pruritus
Abdominal Pain
Fatigue
Stem Cells
Cell Proliferation
Bone and Bones
Drug Therapy

Keywords

  • Essential thrombocythemia
  • Myeloproliferative disorders
  • Myeloproliferative neoplasms
  • Polycythemia vera
  • Primary myelofibrosis

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Quality of Life in MPN Comes of Age as a Therapeutic Target. / Scherber, Robyn M.; Geyer, Holly L.; Mesa, Ruben A.

In: Current Hematologic Malignancy Reports, Vol. 9, No. 4, 2014, p. 324-330.

Research output: Contribution to journalArticle

Scherber, Robyn M. ; Geyer, Holly L. ; Mesa, Ruben A. / Quality of Life in MPN Comes of Age as a Therapeutic Target. In: Current Hematologic Malignancy Reports. 2014 ; Vol. 9, No. 4. pp. 324-330.
@article{93dd3a7c0eba49e587be52d3a37594f2,
title = "Quality of Life in MPN Comes of Age as a Therapeutic Target",
abstract = "BCR-ABL-negative myeloproliferative neoplasms include primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Clonal stem cell proliferation and dysregulated JAK/STAT molecular pathways characterize these hematologic malignancies. Symptoms experienced by patients are heterogeneous including excessive and disabling fatigue, early satiety, anorexia, pruritus, bone pain, night sweats, cachexia, abdominal pain and discomfort, and cognitive complaints. Patients also experience impaired quality of life along with decreased overall survival. New targeted drug therapies, including JAK2 inhibitors, have demonstrated remarkable success in alleviating the myeloproliferative neoplasm (MPN) symptomatic burden, reducing splenomegaly and improving quality of life while offering overall survival benefit. Within the USA, FDA approval has only been granted to use JAK2 inhibitors in intermediate- to high-risk myelofibrosis. However, given that low-prognostic-scoring patients have been shown to have considerable symptomology, there is a possibility that lower-risk patients may benefit from therapy. More than ever, the need for accurate MPN symptom burden assessment and subsequent addition of targeted therapies is critical in the treatment of MPNs. This article discusses the role of MPN symptom burden and quality of life as therapeutic targets in the context of recent MPN clinical advances.",
keywords = "Essential thrombocythemia, Myeloproliferative disorders, Myeloproliferative neoplasms, Polycythemia vera, Primary myelofibrosis",
author = "Scherber, {Robyn M.} and Geyer, {Holly L.} and Mesa, {Ruben A.}",
year = "2014",
doi = "10.1007/s11899-014-0239-9",
language = "English (US)",
volume = "9",
pages = "324--330",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",
number = "4",

}

TY - JOUR

T1 - Quality of Life in MPN Comes of Age as a Therapeutic Target

AU - Scherber, Robyn M.

AU - Geyer, Holly L.

AU - Mesa, Ruben A.

PY - 2014

Y1 - 2014

N2 - BCR-ABL-negative myeloproliferative neoplasms include primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Clonal stem cell proliferation and dysregulated JAK/STAT molecular pathways characterize these hematologic malignancies. Symptoms experienced by patients are heterogeneous including excessive and disabling fatigue, early satiety, anorexia, pruritus, bone pain, night sweats, cachexia, abdominal pain and discomfort, and cognitive complaints. Patients also experience impaired quality of life along with decreased overall survival. New targeted drug therapies, including JAK2 inhibitors, have demonstrated remarkable success in alleviating the myeloproliferative neoplasm (MPN) symptomatic burden, reducing splenomegaly and improving quality of life while offering overall survival benefit. Within the USA, FDA approval has only been granted to use JAK2 inhibitors in intermediate- to high-risk myelofibrosis. However, given that low-prognostic-scoring patients have been shown to have considerable symptomology, there is a possibility that lower-risk patients may benefit from therapy. More than ever, the need for accurate MPN symptom burden assessment and subsequent addition of targeted therapies is critical in the treatment of MPNs. This article discusses the role of MPN symptom burden and quality of life as therapeutic targets in the context of recent MPN clinical advances.

AB - BCR-ABL-negative myeloproliferative neoplasms include primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Clonal stem cell proliferation and dysregulated JAK/STAT molecular pathways characterize these hematologic malignancies. Symptoms experienced by patients are heterogeneous including excessive and disabling fatigue, early satiety, anorexia, pruritus, bone pain, night sweats, cachexia, abdominal pain and discomfort, and cognitive complaints. Patients also experience impaired quality of life along with decreased overall survival. New targeted drug therapies, including JAK2 inhibitors, have demonstrated remarkable success in alleviating the myeloproliferative neoplasm (MPN) symptomatic burden, reducing splenomegaly and improving quality of life while offering overall survival benefit. Within the USA, FDA approval has only been granted to use JAK2 inhibitors in intermediate- to high-risk myelofibrosis. However, given that low-prognostic-scoring patients have been shown to have considerable symptomology, there is a possibility that lower-risk patients may benefit from therapy. More than ever, the need for accurate MPN symptom burden assessment and subsequent addition of targeted therapies is critical in the treatment of MPNs. This article discusses the role of MPN symptom burden and quality of life as therapeutic targets in the context of recent MPN clinical advances.

KW - Essential thrombocythemia

KW - Myeloproliferative disorders

KW - Myeloproliferative neoplasms

KW - Polycythemia vera

KW - Primary myelofibrosis

UR - http://www.scopus.com/inward/record.url?scp=84921936694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921936694&partnerID=8YFLogxK

U2 - 10.1007/s11899-014-0239-9

DO - 10.1007/s11899-014-0239-9

M3 - Article

C2 - 25262210

AN - SCOPUS:84921936694

VL - 9

SP - 324

EP - 330

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

IS - 4

ER -